Systemic lupus erythematosus, or lupus, is a complex autoimmune disease in which the immune system mistakenly attacks healthy ...

Lupus is an autoimmune disease where the body’s immune system attacks its own tissues and organs, causing inflammation and damaging organs.

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of lupus nephritis.

“We are trying to maintain patient programs, but we need funding to do it and that is why the walk is so important," said ...

New research reveals disturbing nightmares and hallucinations may serve as early warning signs of lupus, potentially helping patients receive treatment sooner.

For patients with systemic lupus erythematosus (SLE) and pericarditis, recurrence of pericarditis occurs in more than 20% of patients and associated factors include younger age, prednisone treatment, ...

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...

Despite advancements in the management of systemic lupus erythematosus (SLE), patients experience poor health-related quality of life (hrQoL) and premature death due to disease severity and treatment ...

Roche RHHBY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking label expansion for its ...

Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...